Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab + SOX + IP Nab-paclitaxel in Advanced GC/GEJ With Malignant Ascites
NCT06046963Phase 2Unknown
- Sponsor
- Zhejiang Cancer Hospital
- Start
- Mar 2023
- Primary completion
- Mar 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of sintilimab in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, sponsored by Zhejiang Cancer Hospital. Status: unknown.
02
Drugs
sintilimab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT06046963.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06046963.